Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.61 |
| ▸ | GSK3B | P49841 | 1/20 | 0.57 |
| ▸ | PI4KA | P42356 | 6/20 | 0.54 |
| ▸ | PI4K2B | Q8TCG2 | 6/20 | 0.54 |
| ▸ | PI4K2A | Q9BTU6 | 6/20 | 0.54 |
| ▸ | PI4KB | Q9UBF8 | 6/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.45 |
| ▸ | AHCY | P23526 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21066915 | 0.85 | EGFR (0.65) | EGFRGSK3BPI4KAPI4K2BPI4K2A | |
| SCHEMBL27599134 | 0.82 | GSK3B (0.69) | EGFRGSK3BPI4KAPI4K2BPI4K2A | |
| SCHEMBL6046938 | 0.82 | PI4KA (0.59) | EGFRGSK3BPI4KAPI4K2BPI4K2A | |
| SCHEMBL5694208 | 0.79 | CFTR (0.53) | EGFRADORA2AADORA1 | |
| SCHEMBL5857627 | 0.79 | GSK3B (0.53) | EGFRGSK3BPI4KAPI4K2BPI4K2A | |
| SCHEMBL5694058 | 0.79 | EGFR (0.42) | EGFRADORA2AADORA1AHCY | |
| SCHEMBL2346678 | 0.78 | GSK3B (0.67) | EGFRGSK3BPI4KAPI4K2BPI4K2A | |
| SCHEMBL9682096 | 0.77 | ALDH1A1 (0.44) | EGFRGSK3BADORA2ASRCKDR | |
| Hydrochloric Acid SCHEMBL29003046 | 0.76 | GSK3B (0.65) | EGFRGSK3BPI4KAPI4K2BPI4K2A | |
| SCHEMBL5860316 | 0.76 | AHCY (0.56) | EGFRGSK3BPI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 787 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11987599-B2 | Solid support for synthesizing nucleic acid sequences and methods for making and using | UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-05-21 | — | — | US | claimed |
| CN-117924393-A | Monomer of 3' -mercapto nucleoside analogue and its synthesis process | 天津兴博润生物制药有限公司 | 2024-04-26 | — | — | CN | claimed |
| US-20230271998-A1 | SOLID SUPPORT FOR SYNTHESIZING NUCLEIC ACID SEQUENCES AND METHODS FOR MAKING AND USING | UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-08-31 | — | — | US | claimed |
| US-20220195497-A1 | HYBRIDIZING all-LNA OLIGONUCLEOTIDES | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2022-06-23 | — | — | US | claimed |
| EP-3980554-A1 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | F. Hoffmann-La Roche AG (CH) | 2022-04-13 | — | — | EP | claimed |
| CN-113939599-A | Hybrid all-LNA oligonucleotides | 豪夫迈·罗氏有限公司 | 2022-01-14 | — | — | CN | claimed |
| WO-2022005988-A2 | SOLID SUPPORT FOR SYNTHESIZING NUCLEIC ACID SEQUENCES AND METHODS FOR MAKING AND USING | UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-01-06 | — | — | WO | claimed |
| WO-2020245377-A1 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2020-12-10 | — | — | WO | claimed |
| EP-3004131-B1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | AM CHEMICALS LLC (US) | 2020-07-22 | — | — | EP | claimed |
| CN-106117289-B | 2 '-O-MOE-3 '-H- thiophosphate nucleoside monomers and its synthetic method | 郑州大学 | 2019-02-12 | — | — | CN | claimed |
| EP-0747389-A1 | 3'-SUBSTITUTED NUCLEOSIDE DERIVATIVES | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1996-12-11 | — | — | EP | claimed |
| WO-1996019478-A1 | 6'-SUBSTITUTED CARBOCYCLIC NUCLEOSIDES | NOVARTIS AG (CH) | 1996-06-27 | — | — | WO | claimed |
| WO-1995029930-A2 | IMPROVED METHOD FOR OLIGONUCLEOTIDE ANALOG SYNTHESIS | GILEAD SCIENCES, INC. (US) | 1995-11-09 | — | — | WO | claimed |
| EP-0570514-A4 | METHYLENE PHOSPHONATE NUCLEOSIDE ANALOGS AND OLIGONUCLEOTIDE ANALOGS MADE THEREFROM | GILEAD SCIENCES INC (US) | 1994-08-17 | — | — | EP | claimed |
| WO-1994001445-A1 | BASE-PROTECTED NUCLEOTIDE ANALOGS WITH PROTECTED THIOL GROUPS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1994-01-20 | — | — | WO | claimed |
| EP-0570514-A1 | METHYLENE PHOSPHONATE NUCLEOSIDE ANALOGS AND OLIGONUCLEOTIDE ANALOGS MADE THEREFROM | GILEAD SCIENCES, INC. (US) | 1993-11-24 | — | — | EP | claimed |
| WO-1992013869-A1 | METHYLENE PHOSPHONATE NUCLEOSIDE ANALOGS AND OLIGONUCLEOTIDE ANALOGS MADE THEREFROM | GILEAD SCIENCES, INC. (US) | 1992-08-20 | — | — | WO | claimed |
| WO-1992011276-A1 | NOVEL SYNTHESIS OF 2'-'UP' FLUORINATED 2''-DEOXY-ARABINOFURANOSYLPURINES | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1992-07-09 | — | — | WO | claimed |
| EP-0121112-B1 | 2'-DEOXY-3-PHOSPHONYLMETHYL NUCLEOSIDES AND METHOD FOR THEIR PREPARATION | Gesellschaft für Biotechnologische Forschung mbH (GBF) (DE) | 1987-05-13 | — | — | EP | claimed |
| EP-0121112-A1 | 2'-Deoxy-3-phosphonylmethyl nucleosides and method for their preparation | Gesellschaft für Biotechnologische Forschung mbH (GBF) (DE) | 1984-10-10 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11987599-B2 | Solid support for synthesizing nucleic acid sequences and methods for making and using | RNGTT, NSUN2, POLN | EGFR 1384/4885GSK3B 4778/4885PI4KA 2381/4885 |
| US-20230271998-A1 | SOLID SUPPORT FOR SYNTHESIZING NUCLEIC ACID SEQUENCES AND METHODS FOR MAKING AND USING | RNGTT, NSUN2, POLN | EGFR 1384/4885GSK3B 4778/4885PI4KA 2381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.